Semaglutide for weight loss in advanced interstitial lung

Recruiting

18-99 years

All

Phase N/A

10 participants needed

1 Location

Brief description of study

The aim of the pilot study is to demonstrate feasibility and tolerability of semaglutide in patients with obesity and advanced ILD.

Detailed description of study

Semaglutide is a antidiabetic medication that has been known to help with long-term weight-loss management. The aim is to see the tolerability of the medication in patients with ILDs to promote weight-loss for feasibility of further pulmonary treatment. This is a 22-week study, during which you will be asked to work with the research study team and meet with them to complete research procedures.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research,Interstitial Lung Disease,Obesity
Age: Between 18 Years - 99 Years
Gender: All

- Diagnosis of an Interstitial Lung Disease

- BMI > 35 kg/m²

- Requires supplemental oxygen on exertion

- Semaglutide prescribed by primary pulmonologist

- Insurance approval

Updated on 01 Aug 2024. Study ID: 851742

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).